Similar transactivation by FOS was observed in control and IPF fibroblasts for the M1 mutation compare to the wildtype pP-TFBS-C, while only about two-fold increase in enhancer activity for the M2 mutation was observed in both fibroblasts (Fig 4D). The gene discussed is FOS; the disease is idiopathic pulmonary fibrosis.